Not provided
Not provided
Not provided
Not provided
Not provided
Due to poor enrollment this study was terminated prematurely.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will examine the efficacy, safety and effect on hemoglobin levels, of once weekly subcutaneous injections of epoetin beta (30,000 IU) in anemic participants with non-Hodgkin's lymphoma, chronic lymphocytic leukemia or multiple myeloma. The anticipated study duration is 4 months, and the target sample size is 30 individuals.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Epoetin Beta - 30000 IU | Experimental | Dosage at Initiation: Subcutaneous injection of 30000 IU epoetin beta administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Epoetin Beta | Drug | Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 g/dL versus baseline. |
| Measure | Description | Time Frame |
|---|---|---|
| Hemoglobin levels at 16 weeks | 16 Weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Serum Iron, Ferritin and Transferrin Levels | 16 Weeks | |
| Time to Global Response | Up to 4 months | |
| Percentage of Participants with a Positive Response |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Caracas | 1040 | Venezuela | ||||
Not provided
| ID | Term |
|---|---|
| D000740 | Anemia |
| ID | Term |
|---|---|
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C103998 | epoetin beta |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Weeks 4 and 8 |
| Quality of Life in Relation to Grade of Anemia | Up to 4 months |
| Quality of Life According to the Functional Assessment of Cancer Therapy - Anemia (FACT-An) Instrument | Up to 4 months |
| Tolerability - Incidence of Adverse Events | Up to 16 Weeks of treatment period |
| Caracas |
| 2122 |
| Venezuela |